CMHC enters the week under genuine pressure, down 10% over the past month and 7% in the past week alone, with valuation multiples compressing and earnings momentum that has yet to translate into price recovery.
The price story dominates right now. Cosmo closed at CHF 56.90 on Tuesday, a level that sits well below where the founder was selling in April — Mauro Severino Ajani disposed of over 60,000 shares between mid-April and late April at prices ranging from CHF 98 to CHF 103. That cluster of sales, totalling roughly $7.8m in disclosed value, now looks prescient. The insider data is now four months old, but the direction of travel it signalled has been confirmed by the market. No insider buying has appeared on the register since a single board member picked up 2,886 shares at CHF 92 in March.
The borrow market offers no particular signal either way. Availability remains exceptionally loose — roughly 1,843% of short interest is still available to lend, meaning the lending pool is almost entirely untapped. Cost to borrow has crept up about 7% this week to 0.82%, but remains firmly in "low" territory and has barely moved over the past 30 days. Short interest itself is negligible relative to the float, and the short score of 32 — while nudging higher this week from a low of around 30 last week — remains far from any level that would signal crowded positioning. Bears are not pressing hard here through the lending market. The modest tightening in availability over recent weeks (down roughly 32% from its peak) is more likely a function of the share pool shrinking than any meaningful increase in short demand.
The earnings picture explains some of the recent weakness but does not fully account for the scale of the decline. The last material price reaction was in March, when the stock fell 7.7% on the day of results and extended losses to 20% over the following five days. The more recent July event produced only a flat to marginally negative response — down less than 0.5% on the day and about 5% over five days — consistent with the recent note flagging mixed Q2 numbers, with 3.2% revenue growth undercut by margin compression. No next earnings date is currently scheduled in the data.
Where the data does offer a more positive read is on forward earnings momentum. The EPS momentum scores rank in the 89th and 94th percentiles on 30- and 90-day horizons respectively, and the 12-month forward EPS year-on-year increase ranks in the 91st percentile. Valuation multiples, though compressing, remain meaningful: the P/E has fallen about six points over the past 30 days to roughly 27.8x, and EV/EBITDA has dropped nearly two points to 19.6x. The analyst consensus price target of CHF 131 — though the most recent update was 23 days ago and no target changes have been filed recently — implies substantial upside from current levels. That gap deserves a caveat: with the stock now trading near CHF 57, a mean target of CHF 131 is a more than 2x premium, which warrants caution about whether targets have been refreshed to reflect the recent de-rating. Capital Research and Management Company is notable among recent institutional moves, having initiated or significantly added a 5.7% stake as of June 30.
Among the correlated peers, NWRN on the SWX rallied 8.8% on the week while SNDL fell 5.4% and GSK was roughly flat. Cosmo's 7% weekly decline makes it the clear laggard in its peer group — a divergence worth tracking to determine whether sector-specific pressure or company-specific factors are driving the gap. The next visible catalyst, absent a scheduled earnings date, is whether management provides any interim guidance update or whether the analyst community refreshes its targets in response to the stock's continued move lower.
See the live data behind this article on ORTEX.
Open CMHC on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
